aTYR PHARMA INC
ATYR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001339970
No open-market purchases or sales by aTYR PHARMA INC insiders were filed in the last 90 days; 89 institutions reported holding it in 13F filings for Q2 2026, worth $23.2M in total; no superinvestor holds it.
13F holders, Q1 2023
Institutional positions in aTYR PHARMA INC as of Mar 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 37
- +2 vs. Q4 2022
- Shares held
- 34.7M
- +16.9M (+95.5%) vs. Q4 2022
- Total value
- $72.8M
- +$34.0M (+87.5%) vs. Q4 2022
- New holders
- 12
- 13 more added
- Sold out
- 10
- 7 more reduced
1 institution that held it in Q4 2022 haven't filed for Q1 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ATYR on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 89 | $23.2M |
| Q1 2026 | 111 | $43.7M |
| Q4 2025 | 84 | $42.1M |
| Q3 2025 | 103 | $43.9M |
| Q2 2025 | 110 | $336.5M |
| Q1 2025 | 87 | $186.5M |
| Q4 2024 | 77 | $198.6M |
| Q3 2024 | 56 | $84.3M |
| Q2 2024 | 47 | $75.1M |
| Q1 2024 | 56 | $81.5M |
| Q4 2023 | 46 | $58.1M |
| Q3 2023 | 41 | $58.7M |
| Q2 2023 | 41 | $77.0M |
| Q1 2023 | 37 | $72.8M |
| Q4 2022 | 36 | $40.2M |
| Q3 2022 | 33 | $57.2M |
| Q2 2022 | 36 | $53.1M |
| Q1 2022 | 41 | $105.0M |
| Q4 2021 | 47 | $153.5M |
| Q3 2021 | 42 | $172.1M |
| Q2 2021 | 29 | $33.8M |
| Q1 2021 | 25 | $26.3M |
Institutions, Q1 2023
Shares, value and share of portfolio for each institution holding aTYR PHARMA INC; share changes are against Q4 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Raleigh Capital Management Inc. | 13 | $27 | 0.00% | +13 | New |
| PFS Partners, LLC | 406 | $853 | 0.00% | 00.0% | Unchanged |
| Clearview Wealth Advisors LLC | 500 | $1.05K | 0.00% | +500 | New |
| UBS Group AG | 1,000 | $2.10K | 0.00% | +1,000 | New |
| Tower Research Capital LLC (TRC) | 1,281 | $3.00K | 0.00% | −16,162−92.7% | Reduced |
| Wells Fargo & Company | 1,854 | $3.89K | 0.00% | +159+9.4% | Added |
| Morgan Stanley | 2,284 | $4.80K | 0.00% | +2,284 | New |
| Tocqueville Asset Management L.P. | 10,150 | $21.3K | 0.00% | 00.0% | Unchanged |
| Marshall Wace, LLP | 10,947 | $23.0K | 0.00% | −129,349−92.2% | Reduced |
| Occudo Quantitative Strategies LP | 11,922 | $25.0K | 0.00% | +11,922 | New |
| D.A. Davidson & Co. | 12,000 | $25.2K | 0.00% | −800−6.3% | Reduced |
| Squarepoint Ops LLC | 12,174 | $25.6K | 0.00% | +12,174 | New |
| Charles Schwab Investment Management Inc | 26,689 | $56.0K | 0.00% | +16,689+166.9% | Added |
| Bank of New York Mellon Corp | 35,868 | $75.3K | 0.00% | +35,868 | New |
| Ensign Peak Advisors, Inc | 37,884 | $79.6K | 0.00% | 00.0% | Unchanged |
| Salem Investment Counselors Inc | 40,000 | $84.0K | 0.00% | +40,000 | New |
| Citadel Advisors LLC | 40,929 | $86.0K | 0.00% | +3,092+8.2% | Added |
| Northern Trust Corp | 70,605 | $148.3K | 0.00% | +24,734+53.9% | Added |
| Royal Bank of Canada | 77,073 | $161.0K | 0.00% | +5,305+7.4% | Added |
| Boothbay Fund Management, LLC | 80,000 | $168.0K | 0.00% | +80,000 | New |
| State Street Corp | 82,908 | $174.1K | 0.00% | 00.0% | Unchanged |
| Tang Capital Management LLC | 123,430 | $259.2K | 0.04% | 00.0% | Unchanged |
| Two Sigma Investments, LP | 125,616 | $263.8K | 0.00% | −36,922−22.7% | Reduced |
| JPMorgan Chase & Co | 134,868 | $283.0K | 0.00% | +132,271+5,093.2% | Added |
| Dimensional Fund Advisors LP | 147,773 | $310.3K | 0.00% | −49,919−25.3% | Reduced |
| Two Sigma Advisers, LP | 153,450 | $322.2K | 0.00% | −2,700−1.7% | Reduced |
| Renaissance Technologies LLC | 157,655 | $331.0K | 0.00% | −8,421−5.1% | Reduced |
| BlackRock Inc. | 329,177 | $691.3K | 0.00% | +60,231+22.4% | Added |
| Geode Capital Management, LLC | 578,902 | $1.22M | 0.00% | +336,663+139.0% | Added |
| CVI Holdings, LLC | 588,571 | $1.24M | 0.47% | +588,571 | New |
| Samsara BioCapital, LLC | 1,750,000 | $3.67M | 0.76% | +1,750,000 | New |
| Vanguard Group Inc | 2,094,257 | $4.40M | 0.00% | +954,131+83.7% | Added |
| Tikvah Management LLC | 2,460,833 | $5.17M | 2.12% | +1,110,000+82.2% | Added |
| Alyeska Investment Group, L.P. | 2,473,154 | $5.19M | 0.05% | +1,094,407+79.4% | Added |
| Stonepine Capital Management, LLC | 4,825,722 | $10.1M | 3.40% | +4,825,722 | New |
| FMR LLC | 7,974,307 | $16.7M | 0.00% | +3,622,900+83.3% | Added |
| Federated Hermes, Inc. | 10,189,966 | $21.4M | 0.05% | +4,958,366+94.8% | Added |
| VR Adviser, LLC | 0 | $0 | 0.00% | −1,171,436−100.0% | Sold out |
| Walleye Capital LLC | 0 | $0 | 0.00% | −750,000−100.0% | Sold out |
| Citigroup Inc | 0 | $0 | 0.00% | −428,460−100.0% | Sold out |
| Millennium Management LLC | 0 | $0 | 0.00% | −68,106−100.0% | Sold out |
| Acadian Asset Management LLC | 0 | $0 | 0.00% | −26,419−100.0% | Sold out |
| Wolverine Trading, LLC | 0 | $0 | 0.00% | −22,685−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −12,214−100.0% | Sold out |
| Baker Bros. Advisors LP | 0 | $0 | 0.00% | −8,565−100.0% | Sold out |
| RE Dickinson Investment Advisors, LLC | 0 | $0 | 0.00% | −300−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −64−100.0% | Sold out |
| Telemetry Investments, L.L.C. | – | – | – | – | Not filed |